Ebola virus disease (EVD), also known as Ebola haemorrhagic fever in humans and other primates, is a serious, frequently fatal sickness. Ebola Virus Disease (EVD) is a devastating disease that affects both humans and nonhuman primates. After becoming infected with the virus, symptoms often appear two to three weeks later. Fever, sore throat, muscle soreness, and headaches are generally the first signs. Vomiting, diarrhoea, dermatitis, and reduced liver and renal function are common side effects, and some people bleed internally and externally as a result. The disease kills between 25% and 90% of people affected, with an average death rate of 50%. The most common cause of death is shock from fluid loss, which happens six to 16 days after the first symptoms show. Direct contact with infected body fluids, such as blood from infected humans or other animals, or contact with items that have recently been contaminated with infected body fluids, is how the virus spreads.
Zika virus disease is caused by a virus that is mostly transmitted by Aedes mosquitoes that bite during the day. Fever, rash, conjunctivitis, muscle and joint discomfort, malaise, and headache are all common symptoms. The symptoms usually persist 2–7 days. The majority of those infected with the Zika virus do not experience any symptoms. In Africa, the Americas, Asia, and the Pacific, Zika virus outbreaks have been reported.
Title : Novel nasal formulations containing EC16 to combat long COVID
Stephen Hsu, Augusta University, United States
Title : Selection underlying evolution and spread of SARS-CoV-2 variants
Ranjan Ramasamy, IDFISH Technology, United States
Title : Concept elicitation, cognitive debriefing and usability testing of COVID symptoms diary
Susan M Dallabrida, SPRIM US LLC, United States
Title : Insecticide resistance and use of household insecticides for personal protection: Insights from vector-borne disease outbreaks
Walter Fabricio Silva Martins, LSTM, United Kingdom
Title : Evaluating the effectiveness of antimicrobial stewardship on escherichia coli resistance in patients with urinary tract infection
Paulo Arroyo, Warwick Medical School, United Kingdom
Title : iiCON: Developing the infectious disease innovation ecosystem
Becky Jones-Phillips, Liverpool School of Tropical Medicine, United Kingdom